Back to Directory

Histrelin

Performance & Endurance

GnRH agonist implant for prostate cancer and precocious puberty, year-long subcutaneous implant.

Key Benefits

  • ✓Year-long implant
  • ✓Prostate cancer treatment
  • ✓Treats precocious puberty
  • ✓Once-yearly administration
  • ✓Continuous drug delivery

Dosing Information

Dosage Range
50-65 mg implant
Frequency
Once yearly
Typical Duration
Ongoing yearly replacement

Detailed Protocol

Implanted subcutaneously in upper arm. Lasts 12 months then replaced. Requires minor surgical procedure for insertion and removal. Medical procedure.

About Histrelin

Histrelin (Vantas, Supprelin LA) is a synthetic GnRH agonist available as a subcutaneous implant lasting 12 months. Causes testosterone suppression after initial flare. FDA-approved for prostate cancer and central precocious puberty.

Research Notes

FDA-approved for prostate cancer (Vantas) and precocious puberty (Supprelin LA). Unique 12-month implant provides superior compliance. Requires minor surgical procedure.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Initial testosterone flare
  • •Hot flashes
  • •Implant site reactions
  • •Decreased libido
  • •Fatigue
  • •Requires implantation procedure

Always consult with a healthcare professional before starting any peptide therapy.